Drugs Containing Excipient (Inactive Ingredient) METHYLCELLULOSE

« Back to Dashboard

Branded drugs containing METHYLCELLULOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	DAYPRO	oxaprozin	0025-1381	METHYLCELLULOSE
E-Z-EM Canada Inc	ENTERO VU 24%	barium sulfate	32909-145	METHYLCELLULOSE
LEO Pharma Inc	FINACEA FOAM	azelaic acid	50222-303	METHYLCELLULOSE
ApoPharma USA Inc	FERRIPROX	deferiprone	52609-0007	METHYLCELLULOSE
PD-Rx Pharmaceuticals Inc	DAYPRO	oxaprozin	55289-453	METHYLCELLULOSE

Generic drugs containing METHYLCELLULOSE excipient

Company	Ingredient	NDC	Excipient
Pfizer Laboratories Div Pfizer Inc	oxaprozin	0025-1381	METHYLCELLULOSE
Hikma Pharmaceuticals USA Inc	deferiprone	0054-0711	METHYLCELLULOSE
Teva Pharmaceuticals USA Inc	oxaprozin	0093-0924	METHYLCELLULOSE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	METHYLCELLULOSE
Hikma Pharmaceuticals USA Inc	methocarbamol	0143-1290	METHYLCELLULOSE

Methylcellulose Pharmaceutical Excipient Market: Dynamics, Suppliers, Regulation, and Financial Trajectory

Last updated: October 14, 2026

Methylcellulose is a mature, low-cost cellulose ether used in oral solid doses, modified-release systems, liquid formulations, ophthalmic products, and bulk-forming laxatives. Its pharmaceutical market is stable rather than high growth. Volume is supported by generic drug production, emerging-market manufacturing, and demand for non-animal-derived excipients. Pricing remains constrained by substitution from hypromellose, hydroxypropyl cellulose, sodium carboxymethylcellulose, and synthetic polymers.

Public companies generally do not report methylcellulose revenue separately. A defensible market valuation therefore requires a bottom-up model based on pharmaceutical-grade volume, average selling price, geographic demand, and supplier capacity. Public market reports often combine methylcellulose with broader cellulose ethers, creating wide and inconsistent estimates.

What is methylcellulose and where is it used in pharmaceuticals?

Methylcellulose is a partially methylated cellulose polymer identified by CAS No. 9004-67-5. It is produced by treating purified cellulose with alkali and methylating agents, followed by washing, drying, milling, and classification.

Its pharmaceutical functions include:

Function	Typical application
Binder	Wet granulation and tablet compression
Viscosity modifier	Oral liquids, topical formulations, and ophthalmic products
Film former	Coatings and protective films
Matrix former	Extended-release tablets
Suspending agent	Oral and topical suspensions
Bulk-forming agent	Constipation products
Lubricity and texture modifier	Certain semisolid and oral products

Methylcellulose is thermoresponsive in aqueous systems. It can gel as temperature rises, which distinguishes it from several competing cellulose derivatives. Substitution level, viscosity grade, particle size, moisture, microbial quality, and ash content influence performance.

Methylcellulose should not be confused with hypromellose, also called hydroxypropyl methylcellulose or HPMC. HPMC adds hydroxypropyl substitution and is used more broadly in controlled-release matrices, capsule shells, film coatings, and ophthalmic products.

How large is the pharmaceutical methylcellulose market?

No authoritative public source provides a separately audited global revenue figure for pharmaceutical-grade methylcellulose. Commercial estimates frequently combine methylcellulose with HPMC, ethylcellulose, hydroxyethyl cellulose, or the entire pharmaceutical excipient market. Those estimates are not directly comparable.

A practical market model is:

1. Estimate pharmaceutical-grade methylcellulose volume.
2. Separate oral solid dose, liquid, ophthalmic, topical, and laxative uses.
3. Apply regional average selling prices.
4. Add qualification premiums for compendial, low-endotoxin, and documentation-intensive grades.
5. Exclude food, industrial, construction, and personal-care volumes.

The pharmaceutical segment is smaller than food and industrial methylcellulose markets. Its value per kilogram is higher because of tighter specifications, validated manufacturing, regulatory documentation, and customer qualification requirements.

Indicative market characteristics

Metric	Market implication
Product maturity	Mature excipient with established compendial use
Volume growth	Low single digit in developed markets; potentially higher in emerging markets
Price growth	Usually limited by generic-drug purchasing pressure
Margin profile	Higher for qualified specialty grades than commodity grades
Demand concentration	Oral solid dose and laxative applications account for significant demand
Substitution risk	Moderate to high against HPMC and other cellulose ethers
Customer switching	Low after formulation and supplier qualification
Supply-chain sensitivity	Moderate, with exposure to cellulose feedstock, chemicals, energy, and freight

A market participant should treat any precise global revenue estimate as scenario-based unless the source discloses product-level volume and revenue.

What drives methylcellulose demand?

Generic and contract-manufacturing expansion

Methylcellulose demand tracks the number of tablets, capsules, oral liquids, and topical products manufactured. Generic-drug production is the principal structural demand driver because excipient cost, regulatory acceptability, and supply continuity matter more than brand differentiation.

Growth is strongest in India, China, Southeast Asia, Latin America, and other regions adding oral solid dose capacity. Mature markets generate replacement demand and continued volume from chronic therapies.

Demand for plant-derived excipients

Methylcellulose is derived from cellulose rather than animal tissue. This supports use in vegetarian, vegan, halal, and kosher formulations. The commercial effect is real but limited because other plant-derived cellulose ethers also satisfy many of these requirements.

Modified-release formulation development

Methylcellulose can form hydrophilic matrices and alter drug release. HPMC is more widely selected for controlled-release applications, but methylcellulose remains relevant where gelation, viscosity, or release behavior fits the formulation.

Liquid and ophthalmic formulations

Viscosity modification and suspension stabilization support demand in oral liquids, topical preparations, and ophthalmic products. These applications require control of microbial quality, particulate matter, viscosity, and compatibility with preservatives and active ingredients.

Bulk-forming laxatives

Methylcellulose is used as an active ingredient in some over-the-counter laxative products, not only as an inactive excipient. This creates a separate regulatory and commercial category. The best-known consumer product association is Citrucel, although product ownership, formulation, and market availability vary by jurisdiction.

Which companies supply pharmaceutical-grade methylcellulose?

The competitive field includes multinational excipient suppliers and Asian cellulose-ether manufacturers. Product availability varies by grade and region.

Supplier or supplier group	Relevant positioning
Ashland	Cellulose ether and pharmaceutical excipient portfolio, including Benecel and related technologies
Shin-Etsu Chemical	METOLOSE and related cellulose derivatives, with pharmaceutical and industrial grades
Lotte Fine Chemical	MECELLose and cellulose-ether products
JRS Pharma	Pharmaceutical excipients and cellulose-based formulation materials
Dow legacy portfolio	METHOCEL is a well-known historical brand associated with cellulose ethers
Roquette and other excipient distributors	Distribution, formulation support, and broader excipient portfolios
Chinese and Indian manufacturers	Increasing supply of compendial cellulose ethers and cost-competitive alternatives

Supplier comparisons should focus on the exact polymer, viscosity grade, substitution profile, compendial status, particle-size distribution, change-control history, and manufacturing site. Brand-level comparisons can be misleading because the same nominal viscosity range may produce different hydration, gelation, and tablet-release behavior.

What is the FDA regulatory status of methylcellulose?

Methylcellulose has established regulatory use in the United States. FDA’s Inactive Ingredient Database records excipient use by route, dosage form, and maximum potency information where available [1]. Presence in the database does not constitute blanket approval for every formulation or dose.

Relevant regulatory considerations include:

• United States Pharmacopeia-National Formulary specifications, where applicable.
• FDA inactive-ingredient precedent.
• European Pharmacopoeia and other national pharmacopoeial requirements.
• Food Chemical Codex and E-number status for food applications.
• Good Manufacturing Practice controls.
• Residual solvent, elemental impurity, microbial, and endotoxin controls.
• Supplier change notification and documentation obligations.

The International Council for Harmonisation Q8, Q9, and Q10 frameworks are relevant to excipient selection, formulation development, risk management, and pharmaceutical quality systems [2]. The European Medicines Agency also expects manufacturers to assess excipient quality, function, safety, and control as part of the finished-product dossier [3].

What patents protect methylcellulose products?

Methylcellulose is an established material rather than a newly patented active pharmaceutical ingredient. Broad composition patents covering ordinary pharmaceutical methylcellulose are unlikely to provide meaningful exclusivity for standard grades.

Relevant intellectual-property categories are narrower:

Patent category	Commercial relevance
Manufacturing process patents	Control substitution, viscosity, purification, drying, and particle size
Formulation patents	Use methylcellulose in a specific dosage form or release profile
Combination patents	Combine methylcellulose with another polymer, active ingredient, or excipient
Delivery-system patents	Protect oral, ophthalmic, topical, or depot delivery architecture
Use patents	Cover a defined therapeutic method or product performance
Trade secrets	Often important for process control, hydration behavior, and batch consistency

Patent value depends on claim scope, filing date, prosecution history, jurisdiction, and freedom-to-operate analysis. Supplier brands and product specifications may be protected more effectively through trade secrets, quality systems, customer qualification, and manufacturing know-how than through broad patent claims.

When does methylcellulose lose exclusivity?

Methylcellulose does not have a single drug-style patent-expiration date. It is a multi-source excipient with long-established public use.

For a finished drug product, exclusivity depends on the active pharmaceutical ingredient, formulation, method of use, and drug-specific patents. Methylcellulose itself normally does not create an Orange Book exclusivity period.

The relevant distinction is:

• A conventional methylcellulose excipient has no single market-wide exclusivity date.
• A branded laxative containing methylcellulose may have product-specific trademarks, patents, or regulatory exclusivity.
• A modified-release drug using methylcellulose may be protected by formulation or method-of-use patents belonging to the drug sponsor.
• A supplier may control a particular grade through manufacturing capability and customer qualification rather than legal exclusivity.

What is the Orange Book and Paragraph IV status of methylcellulose?

Methylcellulose is not an FDA-listed active drug with a standalone Orange Book patent estate. The Orange Book applies to approved drug products and their listed patents, not to excipients as a general class [4].

Accordingly:

• There is no general methylcellulose Paragraph IV challenge.
• A Paragraph IV certification may arise for a drug product that uses methylcellulose in a patented formulation.
• Litigation would normally involve the finished drug sponsor and generic applicant, not the excipient market as such.
• FDA’s Orange Book listing does not establish freedom to operate for a formulation using methylcellulose.

Publicly reported litigation involving methylcellulose is more likely to concern a specific branded laxative, drug-delivery system, or formulation patent than the underlying excipient.

How strong is the patent estate for methylcellulose suppliers?

The patent estate is generally weak at the commodity composition level and stronger at the process and application level.

Stronger protection

• Narrow viscosity and substitution specifications linked to a formulation.
• Controlled-release systems with demonstrated performance.
• Low-endotoxin or highly purified grades for sensitive applications.
• Specialized particle engineering.
• Manufacturing processes that reduce variability or improve hydration.
• Proprietary blends of methylcellulose and other polymers.

Weaker protection

• Generic claims to methylcellulose as a cellulose ether.
• Broad claims covering routine tablet binding or viscosity modification.
• Product claims that can be designed around by changing polymer grade or dosage.
• Claims with expired priority dates or narrow prosecution amendments.

The commercial moat is therefore usually operational. It includes validated plants, compendial compliance, regulatory files, technical service, global distribution, and the cost of reformulating and requalifying an excipient supplier.

What manufacturing and supply-chain barriers affect methylcellulose?

Production depends on purified cellulose, caustic treatment, methylating chemistry, solvent recovery, washing, drying, milling, and quality testing. Cost exposure comes from:

• Wood pulp and cotton-linter pricing.
• Methanol or methyl chloride economics.
• Energy and water consumption.
• Environmental controls and waste treatment.
• Freight and inventory requirements.
• Capacity at qualified pharmaceutical sites.
• Customer-specific grade and packaging requirements.

The most important barrier is not chemical complexity alone. It is consistent production across batches with stable substitution, viscosity, hydration, microbial quality, and impurity profiles.

Pharmaceutical customers may take months or years to qualify a replacement supplier. This lowers short-term substitution risk but raises the regulatory burden for suppliers entering established accounts.

How does methylcellulose compare with hypromellose?

Attribute	Methylcellulose	Hypromellose
Chemical substitution	Methyl groups	Methyl and hydroxypropyl groups
Pharmaceutical maturity	High	Very high
Controlled-release use	Established but narrower	Broad and heavily standardized
Capsule-shell use	Limited relative to HPMC	Major application
Supplier competition	Broad	Broad
Substitution risk	Moderate to high	Moderate
Price sensitivity	High in commodity grades	High, with premium specialty grades
Regulatory familiarity	Established	Extensive global precedent

HPMC is generally the stronger commercial competitor because of its broad use in film coatings, hard capsules, ophthalmic products, and hydrophilic matrix tablets. Methylcellulose retains advantages where its thermal gelation, viscosity behavior, or product-specific performance is preferred.

What is the financial trajectory for methylcellulose?

The expected trajectory is steady volume growth with modest pricing power.

Base-case outlook

• Pharmaceutical volume grows with generic manufacturing and emerging-market dosage production.
• Revenue growth remains below higher-value excipient categories such as specialty polymers, lipid systems, and advanced drug-delivery materials.
• Margin expansion depends on premium pharmaceutical grades, technical service, and supply reliability.
• Commodity grades face substitution and procurement pressure.
• Specialty applications can produce better margins but require development support and regulatory documentation.

Upside factors

• Increased use of controlled-release oral products.
• Expansion of pharmaceutical manufacturing in Asia.
• Greater preference for plant-derived excipients.
• Supply disruptions affecting incumbent suppliers.
• New ophthalmic, topical, or specialty oral applications.

Downside factors

• Replacement by HPMC or synthetic polymers.
• Generic-drug price deflation.
• Customer consolidation and tender purchasing.
• Capacity additions in lower-cost manufacturing regions.
• Excipient reformulation to reduce cost or simplify supply chains.
• Regulatory findings involving a supplier, site, or raw material.

For investors, methylcellulose is better viewed as a defensive excipient franchise than as a high-growth pharmaceutical platform. Financial performance is more likely to follow volume, operating efficiency, and portfolio mix than breakthrough formulation innovation.

What licensing deals and litigation affect the market?

Publicly disclosed licensing transactions focused solely on methylcellulose are limited. Commercial relationships usually involve supply agreements, distribution contracts, technology-transfer arrangements, and broader excipient portfolios rather than royalties on the base polymer.

Litigation risk is concentrated in three areas:

1. Finished drug formulations containing methylcellulose.
2. Supplier process and product-quality disputes.
3. Trade-secret or contract claims involving manufacturing know-how and customer supply.

No general market-wide patent settlement controls methylcellulose supply. Generic launch risk arises at the finished-product level, where a drug sponsor’s formulation patent may cover the use of methylcellulose in a particular release system.

What generic launch risks exist for methylcellulose-containing drugs?

A generic applicant can often substitute a comparable excipient, but formulation changes may affect dissolution, viscosity, gelation, tablet hardness, release rate, stability, and bioequivalence.

Risk is highest when:

• Methylcellulose is central to the release mechanism.
• The reference product uses a proprietary grade.
• The formulation has a narrow dissolution specification.
• The product is a complex oral dosage form.
• The dosage form is ophthalmic or topical and sensitive to viscosity or particle quality.
• The sponsor owns formulation patents with detailed polymer limitations.

The excipient itself rarely blocks generic entry. Its functional role can still increase development time and bioequivalence risk.

Key Takeaways

• Methylcellulose is a mature pharmaceutical excipient with stable, low-to-moderate growth.
• Public financial data do not isolate pharmaceutical methylcellulose revenue from broader cellulose-ether sales.
• Generic drugs, oral solid dose production, emerging-market manufacturing, and plant-derived formulation preferences support demand.
• HPMC is the principal competing cellulose ether in many higher-value pharmaceutical applications.
• Commodity methylcellulose has limited composition-patent protection.
• Supplier advantage comes from validated manufacturing, consistency, regulatory files, and customer qualification.
• Methylcellulose has no standalone Orange Book or Paragraph IV exclusivity framework.
• Financial upside is greater in specialty grades and technical applications than in standard commodity grades.
• The market’s primary risks are substitution, procurement pressure, raw-material costs, and supplier qualification events.

FAQs

Is methylcellulose an active pharmaceutical ingredient or an excipient?

It can be either. In most tablets, liquids, coatings, and topical products, it is an excipient. In certain bulk-forming laxative products, methylcellulose is the active ingredient.

Is methylcellulose the same as HPMC?

No. Methylcellulose contains methyl substitution on cellulose. HPMC contains both methyl and hydroxypropyl substitution and has broader use in controlled-release tablets, capsules, coatings, and ophthalmic products.

Can a pharmaceutical company change methylcellulose suppliers without a regulatory filing?

Usually not without assessment. The regulatory impact depends on the dosage form, product specifications, supplier qualification, formulation sensitivity, and jurisdiction. A material change may require notification, prior approval, or supporting comparability data.

Does methylcellulose create freedom-to-operate risk for generic manufacturers?

The excipient alone usually creates limited risk. The main exposure is a patent covering the finished formulation, release mechanism, method of use, or combination of methylcellulose with other formulation components.

Which methylcellulose applications have the strongest growth prospects?

Specialty oral matrices, ophthalmic and topical viscosity modification, high-purity grades, and pharmaceutical production in emerging markets have better prospects than standard tablet-binding applications.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. International Council for Harmonisation. (2009). ICH harmonised tripartite guideline Q8(R2): Pharmaceutical development. https://www.ich.org/page/quality-guidelines

3. European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.